.You are here:Home > Postdoctoral Scientist,Computational epigenomics and Genetics Postdoctoral Scientist, Computational Epigenomics and Genetics The InstituteThe Centre for Genomic Regulation (CRG) is an international biomedical research institute of excellence, based in Barcelona, Spain, with more than 400 scientists from 44 countries.
The CRG is composed of an interdisciplinary, motivated, and creative scientific team supported by flexible administration and high-end innovative technologies.We are seeking a motivated postdoctoral scientist to lead a project in one of these two areas:Analysis and discovery of rare noncoding mutations causing diabetes, using advanced statistical genetics, computational regulatory genomics, and analysis of whole genome sequences in unique patient cohorts.Using computational strategies to develop a high-resolution epigenomic technology with translational potential.About the LabThe Regulatory Genomics and Diabetes lab aims to uncover genetic mechanisms causing diabetes mellitus and to develop therapeutic avenues.
The group is particularly interested in understanding how genomic information directs cell-specific gene expression and pinpointing gene regulatory defects underlying human disease.The team brings together diverse expertise, ranging from work with mutant stem cell-derived beta cell organoids, engineered mouse models, single-cell epigenomics, large-scale genetic screens, statistical genetics, and the integration of genetic and regulatory data.
This multidisciplinary approach allows us to engage in collaborative projects that combine experimental and computational methods, generating new datasets and experimental testing of in silico predictions.
The group is funded by the European Research Council, the Spanish Ministry of Science and Innovation, Generalitat de Catalunya, an AXA chair, European Foundation for the Study of Diabetes, the Marie Sklodowska-Curie Actions program, a CIBERDEM diabetes network, and a collaborative project with biotech.
The lab forms part of international consortia focused on advancing research in regulatory genomics, single-cell genomics, and human genetics.Recent studies from the lab include:A lineage-specific gene transcription and splicing hierarchy that is disrupted in type 2 diabetes.
(In review).Large-scale discovery of molecular targets for precision treatment of HNF1A-deficient diabetes.
(In review).Transcription regulation by long non-coding RNAs and its disease relevance (Nat Rev Mol Cell Biol, 2024).HASTER lncRNA promoter is a cis-acting transcriptional stabilizer of HNF1A (Nat Cell Biol 2022).Pancreas agenesis mutations disrupt a lead enhancer controlling a developmental enhancer cluster.
(Dev Cell, 2022).Human pancreatic islet 3D chromatin architecture provides insights into the genetics of type 2 diabetes (Nat Genet 2019)